USFDA concludes inspection at Torrent Pharmaceuticals’ Bileshwarpura facility
The inspection has been concluded with zero observation
U.S. Food and Drug Administration (USFDA) has concluded the inspection at Torrent Pharmaceuticals’ Bileshwarpura (Oncology) facility. The said inspection was conducted from April 06, 2026 to April 10, 2026. The inspection has been concluded with zero observation.
Torrent Pharmaceuticals (Torrent Pharma) is flagship company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.
